{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T04:15:11Z","timestamp":1728965711053},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of Nanjing University of Chinese Medicine","award":["No. XZR2023075"],"award-info":[{"award-number":["No. XZR2023075"]}]},{"name":"The National Health Commission Health Development Research Center","award":["No. WKZX2023CX020001"],"award-info":[{"award-number":["No. WKZX2023CX020001"]}]},{"name":"Medical Research project of Jiangsu Provincial Health Commission","award":["No. H2023068"],"award-info":[{"award-number":["No. H2023068"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12982-4","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:23:08Z","timestamp":1728922988000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomograms predicting benefit after immunotherapy in oral bifidobacteria supplementation ICC patients: a retrospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Sihui","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuncheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"1","key":"12982_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2. (In eng).","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"12982_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755\u201362. https:\/\/doi.org\/10.1097\/01.sla.0000251366.62632.d3. (In eng).","journal-title":"Ann Surg"},{"issue":"Suppl 1","key":"12982_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G, Cholangiocarcinoma. Epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331. https:\/\/doi.org\/10.1111\/liv.14095. (In eng).","journal-title":"Liver Int"},{"issue":"6","key":"12982_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.021. (In eng).","journal-title":"J Hepatol"},{"issue":"2","key":"12982_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1245\/s10434-007-9627-x","volume":"15","author":"JC Tan","year":"2008","unstructured":"Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma\u2013a population-based study. Ann Surg Oncol. 2008;15(2):600\u20138. https:\/\/doi.org\/10.1245\/s10434-007-9627-x. (In eng).","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"12982_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1007\/s00268-008-9778-3","volume":"32","author":"T Nakagohri","year":"2008","unstructured":"Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg. 2008;32(12):2675\u201380. https:\/\/doi.org\/10.1007\/s00268-008-9778-3. (In eng).","journal-title":"World J Surg"},{"issue":"12","key":"12982_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/jco.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015\u201327. https:\/\/doi.org\/10.1200\/jco.18.02178. (In eng).","journal-title":"J Clin Oncol"},{"issue":"21","key":"12982_CR8","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020. (In eng).","journal-title":"Cell"},{"issue":"3","key":"12982_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.trecan.2018.01.007","volume":"4","author":"D H\u00f8gdall","year":"2018","unstructured":"H\u00f8gdall D, Lewinska M, Andersen JB. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. Trends Cancer. 2018;4(3):239\u201355. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.007. (In eng).","journal-title":"Trends Cancer"},{"issue":"10","key":"12982_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/mt.2015.115","volume":"23","author":"N Woller","year":"2015","unstructured":"Woller N, G\u00fcrlevik E, Fleischmann-Mundt B, et al. Viral infection of Tumors overcomes resistance to PD-1-immunotherapy by broadening Neoantigenome-directed T-cell responses. Mol Ther. 2015;23(10):1630\u201340. https:\/\/doi.org\/10.1038\/mt.2015.115. (In eng).","journal-title":"Mol Ther"},{"issue":"13","key":"12982_CR11","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","volume":"19","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras MC, et al. Integrative Genomic Analysis of Cholangiocarcinoma identifies distinct IDH-Mutant Molecular profiles. Cell Rep. 2017;19(13):2878\u201380. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.008. (In eng).","journal-title":"Cell Rep"},{"issue":"2","key":"12982_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.009. (In eng).","journal-title":"J Hepatol"},{"issue":"3","key":"12982_CR13","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1093\/oncolo\/oyab073","volume":"27","author":"C Monge","year":"2022","unstructured":"Monge C, Pehrsson EC, Xie C, et al. A phase II study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in patients with advanced biliary tract carcinoma. Oncologist. 2022;27(3):e273\u201385. https:\/\/doi.org\/10.1093\/oncolo\/oyab073. (In eng).","journal-title":"Oncologist"},{"key":"12982_CR14","doi-asserted-by":"publisher","unstructured":"Yarchoan M, Cope L, Ruggieri AN, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021;131(24). https:\/\/doi.org\/10.1172\/jci152670. (In eng).","DOI":"10.1172\/jci152670"},{"issue":"5","key":"12982_CR15","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/hep.30482","volume":"69","author":"C Xie","year":"2019","unstructured":"Xie C, Duffy AG, Mabry-Hrones D, et al. Tremelimumab in Combination with microwave ablation in patients with refractory biliary Tract Cancer. Hepatology. 2019;69(5):2048\u201360. https:\/\/doi.org\/10.1002\/hep.30482. (In eng).","journal-title":"Hepatology"},{"issue":"6264","key":"12982_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084\u20139. https:\/\/doi.org\/10.1126\/science.aac4255. (In eng).","journal-title":"Science"},{"issue":"1","key":"12982_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","volume":"15","author":"Y Lu","year":"2022","unstructured":"Lu Y, Yuan X, Wang M, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022;15(1):47. https:\/\/doi.org\/10.1186\/s13045-022-01273-9. (In eng).","journal-title":"J Hematol Oncol"},{"issue":"8","key":"12982_CR18","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190\u20138. https:\/\/doi.org\/10.1002\/ijc.33013. (In eng).","journal-title":"Int J Cancer"},{"issue":"4","key":"12982_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235\u201347. https:\/\/doi.org\/10.1038\/nrd.2015.35. (In eng).","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"12982_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6. (In eng).","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"12982_CR21","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1200690. (In eng).","journal-title":"N Engl J Med"},{"issue":"2","key":"12982_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1305133. (In eng).","journal-title":"N Engl J Med"},{"issue":"3","key":"12982_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2016.0031","volume":"14","author":"DS Ettinger","year":"2016","unstructured":"Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines Insights: Non-small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016;14(3):255\u201364. https:\/\/doi.org\/10.6004\/jnccn.2016.0031. (In eng).","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"12982_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3978\/j.issn.2304-3865.2012.11.05","volume":"2","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS. The B7-H1\/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. Chin Clin Oncol. 2013;2(1):7. https:\/\/doi.org\/10.3978\/j.issn.2304-3865.2012.11.05. (In eng).","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"12982_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2016.4574","volume":"3","author":"R Santana-Davila","year":"2017","unstructured":"Santana-Davila R, Bhatia S, Chow LQ. Harnessing the Immune System as a therapeutic Tool in Virus-Associated Cancers. JAMA Oncol. 2017;3(1):106\u201312. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4574. (In eng).","journal-title":"JAMA Oncol"},{"issue":"1","key":"12982_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cr.2016.153","volume":"27","author":"H Tashiro","year":"2017","unstructured":"Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59\u201373. https:\/\/doi.org\/10.1038\/cr.2016.153. (In eng).","journal-title":"Cell Res"},{"issue":"1","key":"12982_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","volume":"57","author":"WC Palmer","year":"2012","unstructured":"Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57(1):69\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2012.02.022. (In eng).","journal-title":"J Hepatol"},{"issue":"8","key":"12982_CR28","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus Gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803\u201312. https:\/\/doi.org\/10.1111\/liv.15641. (In eng).","journal-title":"Liver Int"},{"issue":"6","key":"12982_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/s2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522\u201332. https:\/\/doi.org\/10.1016\/s2468-1253(22)00043-7. (In eng).","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12982_CR30","doi-asserted-by":"publisher","first-page":"788635","DOI":"10.3389\/fonc.2021.788635","volume":"11","author":"S Zhu","year":"2021","unstructured":"Zhu S, Liu C, Dong Y, Shao J, Liu B, Shen J. A retrospective study of Lenvatinib Monotherapy or Combined with programmed cell death protein 1 antibody in the treatment of patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. Front Oncol. 2021;11:788635. https:\/\/doi.org\/10.3389\/fonc.2021.788635. (In eng).","journal-title":"Front Oncol"},{"key":"12982_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","volume":"162","author":"S Cousin","year":"2022","unstructured":"Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-Avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022;162:161\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.012. (In eng).","journal-title":"Eur J Cancer"},{"issue":"2","key":"12982_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481. (In eng).","journal-title":"N Engl J Med"},{"issue":"10","key":"12982_CR33","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9. (In eng).","journal-title":"Lancet Oncol"},{"issue":"6349","key":"12982_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733. (In eng).","journal-title":"Science"},{"issue":"1","key":"12982_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/01.ju.0000148261.19532.2c","volume":"173","author":"M Sorbellini","year":"2005","unstructured":"Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173(1):48\u201351. https:\/\/doi.org\/10.1097\/01.ju.0000148261.19532.2c. (In eng).","journal-title":"J Urol"},{"issue":"13 Suppl","key":"12982_CR36","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/cncr.24352","volume":"115","author":"K Touijer","year":"2009","unstructured":"Touijer K, Scardino PT. Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer. 2009;115(13 Suppl):3107\u201311. https:\/\/doi.org\/10.1002\/cncr.24352. (In eng).","journal-title":"Cancer"},{"issue":"5","key":"12982_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/01.mou.0000178336.94991.17","volume":"15","author":"BR Lane","year":"2005","unstructured":"Lane BR, Kattan MW. Predicting outcomes in renal cell carcinoma. Curr Opin Urol. 2005;15(5):289\u201397. https:\/\/doi.org\/10.1097\/01.mou.0000178336.94991.17. (In eng).","journal-title":"Curr Opin Urol"},{"issue":"4","key":"12982_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.immuni.2009.08.020","volume":"31","author":"V Gaboriau-Routhiau","year":"2009","unstructured":"Gaboriau-Routhiau V, Rakotobe S, L\u00e9cuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31(4):677\u201389. https:\/\/doi.org\/10.1016\/j.immuni.2009.08.020. (In eng).","journal-title":"Immunity"},{"issue":"1","key":"12982_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41467-017-00729-8","volume":"8","author":"OY Kim","year":"2017","unstructured":"Kim OY, Park HT, Dinh NTH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-\u03b3-mediated antitumor response. Nat Commun. 2017;8(1):626. https:\/\/doi.org\/10.1038\/s41467-017-00729-8. (In eng).","journal-title":"Nat Commun"},{"issue":"6161","key":"12982_CR40","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967\u201370. https:\/\/doi.org\/10.1126\/science.1240527. (In eng).","journal-title":"Science"},{"issue":"11","key":"12982_CR41","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1136\/gutjnl-2019-320105","volume":"69","author":"L Wang","year":"2020","unstructured":"Wang L, Tang L, Feng Y, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8(+) T cells in mice. Gut. 2020;69(11):1988\u201397. https:\/\/doi.org\/10.1136\/gutjnl-2019-320105. (In eng).","journal-title":"Gut"},{"issue":"6510","key":"12982_CR42","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager LF, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369(6510):1481\u20139. https:\/\/doi.org\/10.1126\/science.abc3421. (In eng).","journal-title":"Science"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12982-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:23:57Z","timestamp":1728923037000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12982-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12982"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12982-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for all research protocols was obtained from the Ethics Committee of Jinling Hospital, adhering to the principles outlined in the Declaration of Helsinki. The patients provided written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1274"}}